FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) is a clinical-stage biopharmaceutical company developing a portfolio of small molecules. It's a pharmaceutical company. The company's product candidates to address serious diseases such as oncology and obesity today announced the appointment of Melita Soon-Jong as Chief Business Officer, effective April 22, 2024.
“We are excited to welcome Melita to the Terns leadership team at this important stage in our company's growth,” said Amy Burrows, CEO of Terns. “We have multiple important milestones planned across our oncology and metabolic pipelines, including data readouts from Phase 1 trials of TERN-701 in CML and TERN-601 in obesity, and we are looking forward to valuable partnerships and strategic Melita's expertise in driving decision-making, commercial positioning, and commercial positioning will allow us to advance the program into mid- and late-stage development.”
“I am inspired by Terns' corporate and clinical programs and the tremendous potential of small molecule therapeutics to change people's lives,” said Jung. “With some near-term data readouts and a strong balance sheet, Terns is poised for continued success. We look forward to working with Amy and the Terns team to build value and prepare for this exciting next chapter.” I'm excited to be leading the company.”
Mr. Jung joins Terns with more than 20 years of experience in the life sciences industry, leading corporate strategy and business development, commercial planning and execution, financing and investment management. Most recently, he served as Chief Business Officer for Structure Therapeutics, where he was responsible for the company's business strategy, partnership initiatives, commercial planning, corporate branding and communications. She was part of the management team that completed Structure's approximately $185 million initial public offering (IPO), the first major biotech IPO of 2023. Previously, she served as Senior Vice President and Head of Business Development at Sangamo Therapeutics, a genomics company. She is a pharmaceutical company. There, she led collaborations and licensing agreements with a total potential value of over $6 billion and upfront payments of over $500 million from a wide range of strategic partnerships with Pfizer, Kite (a Gilead company), Biogen, and Novartis. Did.
Her previous experience includes corporate development and commercial roles at Adamus Pharmaceuticals and Ipsen, where she led marketing strategy and contributed to multiple product launches. She began her career in biotechnology venture capital and fund management at Bay City Capital and Lombard Odier Darier Hentsch. Ms. Jung received her bachelor's degree in biology from the University of California, Berkeley.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases such as oncology and obesity. Terns' pipeline includes three clinical-stage development programs, including an allosteric BCR-ABL inhibitor, a small molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator program. For more information, please visit www.ternspharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about the Company within the meaning of the federal securities laws. This includes content relating to the expectations, timing and potential results of the Company's and its partners' clinical trials and other development activities. the potential indications that we target with our small molecule product candidates; the therapeutic potential of our small molecule product candidates; the potential for the mechanisms of action of our product candidates to serve as therapeutic targets for targeted indications; the potential utility and progress of our product candidates in targeted indications, including the clinical utility of the data and endpoints used in our clinical trials; our clinical development plans and activities, including the results of our interactions with regulatory authorities regarding our programs; our expectations regarding the profile of our product candidates, including efficacy, tolerability, safety, metabolic stability, pharmacokinetic profile and potential differentiation compared to other products or product candidates; the Company's plans and ability to continue executing its current development strategy, including potential combinations involving multiple product candidates; the company's plans and expectations regarding key personnel additions; and our expectations regarding the availability and sufficiency of cash resources. All statements, other than statements of historical fact, contained in this press release, including statements regarding the Company's strategy, future financial condition, future operations, future test results, expected costs, prospects, plans, operating objectives, and anticipated markets. (including statements regarding growth) are forward-looking statements. The statement you are looking for. In some cases, the words “aim,” “anticipate,” “anticipate,” “believe,” “consider,” “continue,” “potential,” “design,” and “plan.” You can identify forward-looking statements by terms such as: “estimate”, “expect”, “goal”, “intend”, “may”, “objective”, “plan”, “position”, “could”, “predict”, “seek,” “should,” “target,” “will,” “would,” and other similar expressions that predict or indicate future events or future trends, or their equivalents. Negation of the term. We believe that most of these forward-looking statements are based on our current expectations and estimates regarding future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. , based on predictions and predictions. These forward-looking statements are subject to significant uncertainties and you should not rely on them as predictions of future events. These statements, including risks related to the initiation, cost, timing, progress, results and utility of our current and future research, may cause material fluctuations in actual results and the implementation of our plans. is subject to certain risks and uncertainties. Development activities, preclinical research, and clinical trials. These risks are not all-inclusive. For more information on the risk factors that may affect our actual results, please refer to our SEC filings, including, but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2023. Please refer to the risk factors identified in the document. Except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason.
Terns contact information
Investor
Justin Ng
investor@ternspharma.com
media
jenna urban
Berry & Company Public Relations Department
media@ternspharma.com
